1. Scrip

Merck Confident About Keytruda/Chemo Combo May Date With FDA

 
• By Emily Hayes

Keytruda's share in first-line lung cancer in the US is growing, but Merck's first-quarter sales for the PD-1 inhibitor were below consensus. Future growth may depend on combination treatment with chemotherapy, which the company is confident about the FDA approving this month.

conveyer

Merck & Co. Inc.is confident in the combination of its PD-1 inhibitor Keytruda with chemotherapy ahead of the US FDA's May 10 user fee date for accelerated approval in first-line lung cancer even after a tough quarter marked by sales below consensus for a number of key products and major patent losses.

Keytruda (pembrolizumab) currently is approved as a monotherapy in first-line non-small lung cancer (NSCLC) with high PD-L1 expression, second-line NSCLC with at least 1% PD-L1 expression, refractory classical Hodgkin lymphoma and second-line head & neck cancer

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

China Biopharma Podcast - 14 May 2025 (Chinese Language)

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.

Finance Watch: Funding Alternatives Become The Norm In Tough Public Markets

 
• By Mandy Jackson

Public Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.